Indication
For the treatment of women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) locally advanced or metastatic breast cancer in combination with an aromatase inhibitor (AI) or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

Medicine details

Medicine name:
ribociclib (Kisqali)
SMC ID:
SMC2198
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
TBC